摘要
目的探讨人参皂苷Rb1(GRb1)对脑梗死大鼠血管新生的作用及机制。方法 96只大鼠均制备大脑中动脉梗死(MCAO)模型,造模成功后随机分为对照组、GRb1 2. 5和5 mg/kg组,每组32只。对照组给予生理盐水腹腔注射,GRb1 2. 5和5 mg/kg组分别给予浓度为2. 5、5 mg/kg GRb1治疗。3组均于给药1、3、7、14 d行大鼠神经功能评分,测定梗死区微血管密度及血管内皮生长因子(VEGF)、血管生成素-2(Ang-2)基因和蛋白表达情况。结果给药7、14 d,GRb1 2. 5和5 mg/kg组较对照组神经功能评分显著降低,微血管密度显著升高,VEGF、Ang-2基因及蛋白表达显著上调,且GRb1 5 mg/kg组上述指标升高或降低幅度大于GRb1 2. 5 mg/kg组(P <0. 05)。结论 GRb1可能通过促进VEGF、Ang-2等促血管生成因子的表达,增加梗死区微血管密度,达到改善脑梗死神经功能缺损症状的目的。
Objective To investigate effect and mechanism of Ginsenoside Rb1 (GRb1) on angiogenesis in rats with cerebral infarction. Methods A total of 96 rats were selected for preparation of middle cerebral artery infarction (MCAO) models, and the rats were randomly divided into control group and 2.5 and 5mg/kg GRb1 groups after successful modeling ( n =32 in each group). Control group was injected with physiological saline intraperitoneally, while 2.5 and 5 mg/kg GRb1 groups were treated with 2.5 and 5 mg/kg GRb1 respectively. At 1 st , 3 rd , 7 th and 14 th d of medication, scores of neurological function were detected, and microvessel density, vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) genes and proteins expressions in infarcted area were also detected among three groups. Results At 7 th and 14 th d after medication, in 2.5 and 5 mg/kg GRb1 groups, neurological function scores were significantly lower, while values of microvessel density were significantly higher, and expressions of VEGF and Ang-2 genes and proteins were significantly higher than those in control group, and increased or decreased ranges of the above indexes in 5mg/kg GRb1 group were more than those in 2.5 mg/kg GRb1 group ( P <0.05). Conclusion GRb1 may increase microvessel density in infarcted area by promoting expressions of angiogenic factors such as VEGF and Ang-2 in order to improve neurological deficit symptoms of cerebral infarction.
作者
张潇
张金枝
刘真真
林艳
ZHANG Xiao;ZHANG Jin-zhi;LIU Zhen-zhen;LIN Yan(Department of Neurology, Sichuan Provincial People's Hospital, Sichuan Academy of Medical Sciences, Chengdu 610000, China)
出处
《解放军医药杂志》
CAS
2019年第4期10-15,共6页
Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金
四川省卫生和计划生育委员会科研项目(120063)